Brainstorm Cell Therapeutics Inc.

$BCLI is the biggest loser of the Prism MarketView Public Health index. News today came out that the U.S. Food and Drug Administration’s staff reviewers raised concerns over the safety and efficacy of BrainStorm Cell Therapeutics therapy for a rare and fatal neurodegenerative disease called amyotrophic lateral sclerosis (ALS)

Share This Article

 

About the Author

Brainstorm Cell Therapeutics Inc.

Joey Ramson